Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:alternativeName |
AVB-S6-500
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2023)
|
| gptkbp:developedBy |
Aravive, Inc.
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:investigatedBy |
gptkb:cancer
gptkb:renal_cell_carcinoma |
| gptkbp:mechanismOfAction |
AXL receptor tyrosine kinase inhibitor
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
AXL protein
|
| gptkbp:bfsParent |
gptkb:Aravive
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
batiraxcept
|